期刊
IMMUNITY
卷 54, 期 6, 页码 1276-+出版社
CELL PRESS
DOI: 10.1016/j.immuni.2021.03.023
关键词
-
类别
资金
- King's Together Rapid
- UK Medical Research Council (MRC) [MC/PC/15068]
- Fondation Dormeur, Vaduz
- Huo Family Foundation
- MRC Programme Grant [MR/S023747/1]
- Wellcome Trust [208354/Z/17/Z, 106223/Z/14/Z]
- NIAID [U54 AI150472, AI076119]
- UK CIC (Covid-Immunology-Consortium)
- Rosetrees Trust
- UCL Coronavirus Response Fund
- National Institute for Health Research Clinician Scientist Award [CS-2016-16-011]
- European Union [RIA2020EF-3008]
- MRC-KCL Doctoral Training Partnership in Biomedical Sciences [MR/N013700/1]
- MRC-KCL Doctoral Training Partnership in Biomedical Sciences industrial Collaborative Award in Science & Engineering (iCASE)
- Orchard Therapeutics [MR/R015643/1]
- Francis Crick Institute [FC001061]
- Cancer Research UK
- UK Medical Research Council
- Medical Research Council [MR/S007555/1]
- Wellcome Centre [203141/Z/16/Z]
- Medical Research Council Career Development Award [MR/R008698/1]
- Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London
- King's College Hospital NHS Foundation Trust
- Wellcome Trust [208354/Z/17/Z] Funding Source: Wellcome Trust
- MRC [MR/S023747/1] Funding Source: UKRI
The interaction between the SARS-CoV-2 Spike receptor binding domain (RBD) and the host cell receptor ACE2 is crucial for viral entry, with RBD being the main target for neutralizing antibodies. Mutations in RBD, N-terminal domain (NTD), and S2 subunits of Spike have been found in circulating SARS-CoV-2 variants. This study isolates and characterizes monoclonal antibodies targeting different epitopes on RBD, NTD, and S2 to understand how these mutations affect antigenicity and neutralization resistance.
Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which similar to 20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycandependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据